Demonstration venue · read-only. Every page can be browsed; the buttons that would change it are switched off. Create an account to run TaxoReview on your own data. A simulation from public publication records: the people listed were not invited and did not agree to review.
? Tutorial for this page

Xueliang Li 0017

dblp:392/7547 · DBLP profile ↗
← Back
1ranked-venue papers
1as first author
1since 2021 · last 2024
0009-0008-7726-8298ORCID · verified

Domains — the database's venue-derived domains; a paper can count in several

Applied, interdisciplinary, general and emerging computing · 1 · 1 first-author · 1 since 2021

Expertise — from the expertise taxonomy: the topics of the expert's papers under the CCF categories. A weight counts papers with recency: 1 for a paper about the topic, 0.3 when the topic is its context, halved every five years.

Interdisciplinary, comprehensive, and emerging computing
1 paper
Bioinformatics and computational biology · 83% Medical and health informatics · 17%

Topics — the 5 heaviest of 5, each with the papers that count most for it

TopicWeightPapersLastEvidence papers
Bioinformatics and computational biology › drug discovery
drug combination prediction
0.812024
Dual-view jointly learning improves personalized drug synergy prediction · Bioinform. 2024
Bioinformatics and computational biology
drug discovery
0.812024
Dual-view jointly learning improves personalized drug synergy prediction · Bioinform. 2024
Bioinformatics and computational biology › drug discovery › drug combination prediction
drug synergy prediction
0.812024
Dual-view jointly learning improves personalized drug synergy prediction · Bioinform. 2024
Medical and health informatics › precision medicine
personalized treatment
0.212024
Dual-view jointly learning improves personalized drug synergy prediction · Bioinform. 2024
Medical and health informatics
precision medicine
0.212024
Dual-view jointly learning improves personalized drug synergy prediction · Bioinform. 2024

Methods — techniques the papers use, named apart from their topics

fine-tuning · 0.8dual-view jointly learning · 0.8
YearPublicationVenuePosition
2024 Dual-view jointly learning improves personalized drug synergy prediction
abstract
MOTIVATION: Accurate and robust estimation of the synergistic drug combination is important for medicine precision. Although some computational methods have been developed, some predictions are still unreliable especially for the cross-dataset predictions, due to the complex mechanism of drug combinations and heterogeneity of cancer samples. RESULTS: We have proposed JointSyn that utilizes dual-view jointly learning to predict sample-specific effects of drug combination from drug and cell features. JointSyn outperforms existing state-of-the-art methods in predictive accuracy and robustness across various benchmarks. Each view of JointSyn captures drug synergy-related characteristics and makes complementary contributes to the final prediction of the drug combination. Moreover, JointSyn with fine-tuning improves its generalization ability to predict a novel drug combination or cancer sample using a small number of experimental measurements. We also used JointSyn to generate an estimated atlas of drug synergy for pan-cancer and explored the differential pattern among cancers. These results demonstrate the potential of JointSyn to predict drug synergy, supporting the development of personalized combinatorial therapies. AVAILABILITY AND IMPLEMENTATION: Source code and data are available at https://github.com/LiHongCSBLab/JointSyn.
Xueliang Li 0017, Bihan Shen, Fangyoumin Feng, Kunshi Li, Zhixuan Tang, Liangxiao Ma
Bioinform.1